Novartis AG Operating Income 2006-2019 | NVS
Novartis AG annual/quarterly operating income history and growth rate from 2006 to 2019. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Novartis AG operating income for the quarter ending September 30, 2019 was $2.358B, a 5.31% increase year-over-year.
- Novartis AG operating income for the twelve months ending September 30, 2019 was $8.391B, a 7.9% decline year-over-year.
- Novartis AG annual operating income for 2018 was $8.169B, a 5.33% decline from 2017.
- Novartis AG annual operating income for 2017 was $8.629B, a 4.37% increase from 2016.
- Novartis AG annual operating income for 2016 was $8.268B, a 7.9% decline from 2015.
Novartis AG Annual Operating Income
(Millions of US $) |
| 2018 |
$8,169 |
| 2017 |
$8,629 |
| 2016 |
$8,268 |
| 2015 |
$8,977 |
| 2014 |
$11,089 |
| 2013 |
$10,983 |
| 2012 |
$11,507 |
| 2011 |
$10,780 |
| 2010 |
$11,526 |
| 2009 |
$9,982 |
| 2008 |
$8,964 |
| 2007 |
$6,781 |
| 2006 |
$7,642 |
| 2005 |
$6,507 |
Novartis AG Quarterly Operating Income
(Millions of US $) |
| Q3 2019 |
$2,358 |
| Q2 2019 |
$2,663 |
| Q1 2019 |
$2,242 |
| Q4 2018 |
$1,128 |
| Q3 2018 |
$2,239 |
| Q2 2018 |
$2,431 |
| Q1 2018 |
$2,371 |
| Q4 2017 |
$2,070 |
| Q3 2017 |
$2,357 |
| Q2 2017 |
$2,280 |
| Q1 2017 |
$1,922 |
| Q4 2016 |
$1,455 |
| Q3 2016 |
$2,269 |
| Q2 2016 |
$2,093 |
| Q1 2016 |
$2,451 |
| Q4 2015 |
$1,677 |
| Q3 2015 |
$2,234 |
| Q2 2015 |
$2,281 |
| Q1 2015 |
$2,785 |
| Q4 2014 |
$2,351 |
| Q3 2014 |
$2,739 |
| Q2 2014 |
$3,184 |
| Q1 2014 |
$2,815 |
| Q4 2013 |
$2,496 |
| Q3 2013 |
$2,558 |
| Q2 2013 |
$3,033 |
| Q1 2013 |
$2,896 |
| Q4 2012 |
$2,715 |
| Q3 2012 |
$2,948 |
| Q2 2012 |
$3,108 |
| Q1 2012 |
$2,736 |
| Q4 2011 |
$1,099 |
| Q3 2011 |
$2,951 |
| Q2 2011 |
$3,322 |
| Q1 2011 |
$3,408 |
| Q4 2010 |
$2,467 |
| Q3 2010 |
$2,587 |
| Q2 2010 |
$2,961 |
| Q1 2010 |
$3,511 |
| Q4 2009 |
$2,637 |
| Q3 2009 |
$2,634 |
| Q2 2009 |
$2,364 |
| Q1 2009 |
$2,347 |
| Q4 2008 |
$1,680 |
| Q3 2008 |
$2,335 |
| Q2 2008 |
$2,461 |
| Q1 2008 |
$2,488 |
| Q4 2007 |
$897 |
| Q3 2007 |
$1,452 |
| Q2 2007 |
$2,097 |
| Q1 2007 |
$2,335 |
| Q4 2006 |
$1,641 |
| Q3 2006 |
$1,979 |
| Q2 2006 |
$1,964 |
| Q1 2006 |
$2,058 |
| Q4 2005 |
$1,090 |
| Q3 2005 |
$1,888 |
| Q2 2005 |
$1,849 |
| Q1 2005 |
$1,680 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$208.600B |
$51.900B |
|
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
|
